Drugs / PF-06815345
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02654899 | Nov 2015 → Mar 2016 | hyperlipidemia | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06815345 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02654899 ↗ |
| Modality | Small molecule | — CHEMBL4227721 ↗ |
| Route | Oral | “single oral doses of PF-06815345” NCT02654899 ↗ |